Hypofractionated Radiotherapy for Localised Prostate Cancer. Review of Clinical Trials

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2009 Jul 4

PMID 19574201

Citations 14

Authors

Victor Macias

Albert Biete

Affiliations

Soon will be listed here.

Abstract

Over the last 10 years the radiobiology of prostate cancer has been studied both in experimental research and in clinical trials of hypofractionated radiotherapy. Unlike most cancers, the alpha/beta ratio of the prostatic carcinoma is probably lower than that of the healthy organs around the gland, although there is no agreement as to how low this alpha/beta really is. This peculiarity implies that, theoretically, a hypofractionated schedule would increase the therapeutic gain of radiotherapy. Until now, following four published randomised trials, hypofractionated radiotherapy has shown results in terms of acute and chronic toxicity and tumour control similar to those obtained with conventionally fractionated radiotherapy. However, these studies are not conclusive. The two studies that involved significant followup used 2D technique and delivered low total equivalent dose. On the other hand, the two most recent trials, which administered total equivalent doses = or >78 Gy with modern techniques (IMRT, IGRT), involved the disadvantage of small samples and a short follow-up period. The results of ongoing randomised trials are necessary to confirm the advantages of hypofractionation over normofractionated radiotherapy. The impact of hypofractionated radiotherapy on the patient's health-related quality of life, and on transports and health care costs, should also be investigated.

Citing Articles

Hybrid Tomo-Helical and Tomo-Direct radiotherapy for localized prostate cancer.

Karaca S, Koca T, Sarpun I, Tuncel N, Korcum Sahin A J Appl Clin Med Phys. 2021; 22(10):136-143.

PMID: 34498363 PMC: 8504587. DOI: 10.1002/acm2.13406.

Cost-containment in hypofractionated radiation therapy: a literature review.

Hunter D, Mauldon E, Anderson N J Med Radiat Sci. 2018; 65(2):148-157.

PMID: 29532613 PMC: 5985996. DOI: 10.1002/jmrs.273.

Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study.

Gresswell S, Wegner R, Werts D, Miller R, Fuhrer R Adv Radiat Oncol. 2017; 1(4):317-324.

PMID: 28740903 PMC: 5514232. DOI: 10.1016/j.adro.2016.08.005.

Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.

Bracci S, Osti M, Agolli L, Bertaccini L, De Sanctis V, Valeriani M Radiat Oncol. 2016; 11:78.

PMID: 27276878 PMC: 4898326. DOI: 10.1186/s13014-016-0656-0.

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Rucinska M, Kieszkowska-Grudny A, Nawrocki S Strahlenther Onkol. 2016; 192(7):449-57.

PMID: 27221312 PMC: 4919372. DOI: 10.1007/s00066-016-0971-2.

References

Livsey J, Cowan R, Wylie J, Swindell R, Read G, Khoo V . Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis. Int J Radiat Oncol Biol Phys. 2003; 57(5):1254-9. DOI: 10.1016/s0360-3016(03)00752-1. View

King C, Brooks J, Gill H, Pawlicki T, Cotrutz C, Presti Jr J . Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2008; 73(4):1043-8. DOI: 10.1016/j.ijrobp.2008.05.059. View

Junius S, Haustermans K, Bussels B, Oyen R, Vanstraelen B, Depuydt T . Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. Radiat Oncol. 2007; 2:29. PMC: 1971267. DOI: 10.1186/1748-717X-2-29. View

Carlone M, Wilkins D, Nyiri B, Raaphorst P . TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity. Med Phys. 2004; 31(5):1176-82. DOI: 10.1118/1.1711415. View

Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

Wang C, Leung S, Chen H, Sun L, Fang F, Huang E . The correlation of acute toxicity and late rectal injury in radiotherapy for cervical carcinoma: evidence suggestive of consequential late effect (CQLE). Int J Radiat Oncol Biol Phys. 1998; 40(1):85-91. DOI: 10.1016/s0360-3016(97)00560-9. View

Ishikawa H, Tsuji H, Kamada T, Yanagi T, Mizoe J, Kanai T . Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol. 2006; 81(1):57-64. DOI: 10.1016/j.radonc.2006.08.015. View

Yoshioka Y, Konishi K, Oh R, Sumida I, Yamazaki H, Nakamura S . High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol. 2006; 80(1):62-8. DOI: 10.1016/j.radonc.2006.06.011. View

Koukourakis M, Touloupidis S, Manavis J, Abatzoglou I, Sismanidou K, Sivridis L . Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience. Anticancer Res. 2004; 24(5B):3239-43. View

10.

Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T . Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol. 2005; 75(1):74-82. DOI: 10.1016/j.radonc.2004.12.019. View

11.

Madsen B, Hsi R, Pham H, Fowler J, Esagui L, Corman J . Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007; 67(4):1099-105. DOI: 10.1016/j.ijrobp.2006.10.050. View

12.

van der Kogel A, Jarrett K, Paciotti M, Raju M . Radiation tolerance of the rat rectum to fractionated X-rays and pi-mesons. Radiother Oncol. 1988; 12(3):225-32. DOI: 10.1016/0167-8140(88)90265-4. View

13.

Higgins G, McLaren D, Kerr G, Elliott T, Howard G . Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006; 65(4):982-9. DOI: 10.1016/j.ijrobp.2006.02.029. View

14.

Norkus D, Valuckas K, Miller A, Plieskiene A, Kurtinaitis J . [A preliminary safety study of hypofractionated radiotherapy for local prostate cancer]. Medicina (Kaunas). 2006; 41(12):1035-41. View

15.

Pollack A, Hanlon A, Horwitz E, Feigenberg S, Konski A, Movsas B . Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys. 2005; 64(2):518-26. PMC: 1892754. DOI: 10.1016/j.ijrobp.2005.07.970. View

16.

Hannoun-Levi J, Benezery K, Bondiau P, Chamorey E, Marcie S, Gerard J . [Robotic radiotherapy for prostate cancer with CyberKnife]. Cancer Radiother. 2007; 11(8):476-82. DOI: 10.1016/j.canrad.2007.07.005. View

17.

Wyatt R, Beddoe A, Dale R . The effects of delays in radiotherapy treatment on tumour control. Phys Med Biol. 2003; 48(2):139-55. DOI: 10.1088/0031-9155/48/2/301. View

18.

Smit W, Helle P, van Putten W, Wijnmaalen A, Seldenrath J, van der Werf-Messing B . Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990; 18(1):23-9. DOI: 10.1016/0360-3016(90)90262-i. View

19.

Brenner D, Martinez A, Edmundson G, Mitchell C, Thames H, Armour E . Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002; 52(1):6-13. DOI: 10.1016/s0360-3016(01)02664-5. View

20.

Dorr W, Hendry J . Consequential late effects in normal tissues. Radiother Oncol. 2001; 61(3):223-31. DOI: 10.1016/s0167-8140(01)00429-7. View